Clinical interest of the combined use of serum CD26 and alpha-L-fucosidase in the early diagnosis of colorectal cancer.
The purpose of this study was to assess if the combination of CD26 and alpha-L-fucosidase has a role in the diagnosis of colorectal cancer, paying particular attention to the stages in which the tumour is not yet disseminated. CD26 concentration and alpha-L-fucosidase activity were determined in sera from 110 colorectal cancer patients and 46 donors. The combination of CD26 and alpha-L-fucosidase showed a specificity of 100% with a sensitivity of 64% in the diagnosis of colorectal cancer. Interestingly, the combination of both markers had a sensitivity of 75% in the stage I at the highest specificity (100%), providing also high sensitivity levels for the other non-disseminated stages (66% for stages II and III). In conclusion, the combined use of CD26 and alpha-L-fucosidase offers high sensitivity with high specificity in the diagnosis of colorectal cancer, especially at the earliest stage (TNM I).
Ayude
Daniel
D
Department of Biochemistry, Genetics, and Immunology, University of Vigo 36200 Vigo, Spain.
Páez de la Cadena
María
M
Cordero
Oscar Javier
OJ
Nogueira
Montserrat
M
Ayude
José
J
Fernández-Briera
Almudena
A
Rodríguez-Berrocal
Francisco Javier
FJ
D002272:Carcinoembryonic Antigen / Q000032:analysis; D015179:Colorectal Neoplasms / Q000097:blood / Q000145:classification / Q000175:diagnosis*; D018819:Dipeptidyl Peptidase 4 / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D009780:Occult Blood; D012680:Sensitivity and Specificity; D005644:alpha-L-Fucosidase / Q000097:blood*
D002272:Carcinoembryonic Antigen; D005644:alpha-L-Fucosidase; D018819:Dipeptidyl Peptidase 4